Zydus receives final approval from the USFDA for Doxycycline Hyclate Capsules USP

Zydus receives final approval from the USFDA for Doxycycline Hyclate Capsules USP Ahmedabad, 02 June, 2018 Zydus Cadila has received the final approval from the USFDA to market Doxycycline Hyclate Capsules USP, 50 mg and 100 mg. It is a tetracycline antibiotic used for treatment of a wide variety of bacterial infections, including those that cause acne. This medication is also used for prophylaxis of malaria. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The group now has more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗